U.S. Specialty Stores Stock News

NYSE:CXW
NYSE:CXWCommercial Services

CoreCivic (CXW) Valuation Check After Recent Trading Performance And Mixed Earnings Signals

CoreCivic Stock Moves After Recent Trading Performance CoreCivic (CXW) has drawn fresh attention after a recent move that leaves the stock at $19.95, with a roughly 10% gain over the past month and a small decline over the past year. See our latest analysis for CoreCivic. That recent 9.6% 1 month share price return sits alongside a 4.9% year to date share price return and a 3 year total shareholder return of about 120%, suggesting momentum has been built over time despite a weaker 1 year...
NYSE:JNJ
NYSE:JNJPharmaceuticals

One Off Gain Driven Margin Surge Tests Bullish Johnson & Johnson (JNJ) Narratives

Johnson & Johnson (JNJ) has opened Q1 2026 with investors focused on how its recent run of earnings ties back to underlying profitability, after reporting Q4 2025 revenue of US$24.6 billion and basic EPS of US$2.10 alongside trailing twelve month EPS of US$11.13 and revenue of US$94.2 billion. Over the last few quarters the company has seen revenue range from US$21.9 billion in Q1 2025 to US$24.6 billion in Q4 2025, while quarterly basic EPS has moved between US$1.41 in Q4 2024 and US$4.57 in...
NasdaqGS:SOFI
NasdaqGS:SOFIConsumer Finance

Is It Too Late To Reassess SoFi Technologies (SOFI) After Its Volatile Share Price Swings?

If you are wondering whether SoFi Technologies at around US$17.91 is priced for opportunity or already reflecting the story, the key is to understand what the current valuation is really saying. The stock has been volatile, with returns of 8.6% over the last 7 days, 1.6% over 30 days, a 34.8% decline year to date, and a 68.0% return over the last year. These moves can shift how the market is pricing both growth potential and risk. Recent headlines have focused on SoFi's position in consumer...
NYSE:CAH
NYSE:CAHHealthcare

Cardinal Health Report Highlights Community Therapies And Raises New Investor Questions

Cardinal Health released its 2026 Advanced Therapies Report, focusing on how advanced treatments are shifting toward community-based care. The report outlines how providers are rethinking care delivery models to widen patient access outside traditional hospital settings. Findings add new detail to Cardinal Health's role in advanced therapies beyond its previously covered radiopharmaceutical expansions. For investors watching Cardinal Health (NYSE:CAH), the new report lands at a time when...
NasdaqGS:CGNX
NasdaqGS:CGNXElectronic

Cognex (CGNX) Valuation Check As Cost Cuts And AI Expansion Aim To Support Future Earnings

Cognex (CGNX) is back in focus after management outlined plans to cut annual operating costs by about US$35 million to US$40 million, while leaning harder into AI driven machine vision and broader customer reach. See our latest analysis for Cognex. The announcement appears to have come after a sharp shift in sentiment, with a 50.50% year-to-date share price return and a 133.45% total shareholder return over the past year suggesting building momentum rather than a slow grind higher. If you are...
NasdaqGM:LGND
NasdaqGM:LGNDPharmaceuticals

Ligand Pharmaceuticals (LGND) Is Up 13.3% After Securing 9% Royalty on Newly Approved FILSPARI

Ligand Pharmaceuticals recently reported that its partner Travere Therapeutics received full FDA approval for FILSPARI (sparsentan) to reduce proteinuria in adult and pediatric focal segmental glomerulosclerosis (FSGS) patients, the first and only approved treatment for this rare kidney disorder. This approval secures a 9% royalty on worldwide FILSPARI sales for Ligand, potentially strengthening its high-margin royalty portfolio in a specialized nephrology market. Next, we’ll examine how...
NYSE:DVN
NYSE:DVNOil and Gas

Devon And Coterra Merger Reshapes Scale Capital Structure And Shareholder Mix

Devon Energy (NYSE:DVN) has announced a proposed all stock merger with Coterra Energy, outlining plans for a combined business structure. The company has released unaudited pro forma combined financial statements to illustrate the expected scale and corporate setup of the merged entity. Devon has also filed a shelf registration to allow for potential issuance of various securities in connection with future financing needs. Shares of Devon Energy trade around $45.25, with the stock up 19.5%...
NasdaqGS:REPL
NasdaqGS:REPLBiotechs

Why Replimune Group (REPL) Is Down 75.0% After FDA Rejects RP1 Melanoma Application And What's Next

Replimune Group, Inc. recently received a complete response letter from the FDA rejecting its Biologics License Application for RP1 plus nivolumab in advanced melanoma, despite earlier breakthrough therapy designation and priority review based on the IGNYTE trial data set. The company is publicly challenging what it calls inconsistent FDA processes and shifting review teams, highlighting broader tensions around accelerated approvals for oncology drugs. Next, we’ll examine how the FDA’s...
NasdaqGS:SEIC
NasdaqGS:SEICCapital Markets

A Look At SEI Investments (SEIC) Valuation After Recent Mixed Short Term Returns

SEI Investments (SEIC) has drawn fresh attention after recent trading left the stock with mixed short term returns, including a small move over the past week and a flat month, while the 1 year total return remains positive. See our latest analysis for SEI Investments. The recent 6.2% 7 day share price return contrasts with weaker 3 month and year to date share price returns. However, multi year total shareholder returns remain solid, which suggests momentum has cooled even as long term...
NYSE:LNN
NYSE:LNNMachinery

A Look At Lindsay (LNN) Valuation After Weaker Second Quarter Sales And Earnings

Earnings slide puts Lindsay (LNN) under closer investor scrutiny Lindsay (LNN) has moved into focus after reporting a year over year decline in both sales and net income for its second quarter and first half of fiscal 2026. The company posted second quarter sales of US$157.72 million and net income of US$12.05 million, compared with US$187.06 million and US$26.58 million a year earlier. This has prompted investors to reassess recent share performance. See our latest analysis for...
OTCPK:DIDI.Y
OTCPK:DIDI.YTransportation

DiDi’s New L4 Robotaxi Rollout Could Be A Game Changer For DiDi Global (DIDI.Y)

DiDi Global’s autonomous driving unit recently unveiled a next‑generation Robotaxi co-developed with GAC Aion, featuring upgraded L4-level self-driving capabilities, an enhanced smart cockpit, and the start of on-road testing. CEO Zhang Bo’s emphasis on a hybrid mobility network that blends human-driven and autonomous vehicles underlines DiDi’s pragmatic approach to deploying AI in complex real-world traffic conditions. We will now examine how DiDi’s focus on a hybrid human-autonomous...
NYSE:BKV
NYSE:BKVOil and Gas

Could Truist’s Focus on BKV’s Integrated Gas-to-Power Model Reframe the Core BKV (BKV) Story?

Earlier this month, Truist Securities initiated coverage on BKV Corporation, highlighting its low-risk, cash-generating natural gas operations alongside emerging power and carbon capture businesses. The broker’s focus on BKV’s integrated model, spanning upstream production, midstream, power generation and carbon capture, underlines how the company is positioned at the intersection of conventional gas and lower-carbon energy solutions. We’ll now explore how Truist’s emphasis on BKV’s...
NasdaqGM:SEPN
NasdaqGM:SEPNPharmaceuticals

Assessing Septerna (SEPN) Valuation After First Dosing In SEP-479 Phase 1 Trial

Septerna (SEPN) has begun dosing the first participants in its Phase 1 trial of SEP-479, an oral PTH1R agonist for hypoparathyroidism, marking a key milestone that now puts early safety data in focus. See our latest analysis for Septerna. The Phase 1 dosing update comes as Septerna’s share price sits at $24.13, with a 1-day share price return of 3.38% contrasting with a 90-day share price return of a 9.73% decline and a 1-year total shareholder return of 283.62%. This suggests earlier...
NasdaqGS:INCY
NasdaqGS:INCYBiotechs

Assessing Incyte (INCY) Valuation After New Adagene Collaboration In Colorectal Cancer

Clinical collaboration puts fresh focus on Incyte stock Incyte (INCY) is back on investor radars after Adagene announced a clinical collaboration, pairing muzastotug with Incyte’s bispecific antibody INCA33890 in microsatellite stable colorectal cancer. The planned Phase 1 study, expected to start in 2026, will be sponsored and conducted by Incyte. It will initially assess safety and tolerability before moving into an efficacy expansion cohort. See our latest analysis for Incyte. The...
NYSE:NE
NYSE:NEEnergy Services

Does Noble (NE) Really Gain Strategic Leverage From Tighter Offshore Drilling Supply?

Noble Corporation plc has already reported its first-quarter 2026 results on April 26, 2026, followed by a conference call on April 27, with materials made available on its website. At the same time, Noble and peer Seadrill have drawn attention as beneficiaries of rising energy prices and tighter offshore drilling supply, reinforcing the perception that leading offshore contractors are well placed in a consolidating sector. We’ll now consider how Noble’s positioning as a beneficiary of...
NYSE:GLOB
NYSE:GLOBIT

A Look At Globant (GLOB) Valuation After New Autodesk Digital Twin Partnership Expansion

Globant (GLOB) has been named an Autodesk Tandem Digital Twin Solution Provider, expanding a 15 year collaboration to support digital twin deployments across airports, smart buildings, manufacturing facilities and logistics environments worldwide. See our latest analysis for Globant. The recent client wins in digital twins and AI based compliance come against a backdrop of a 31.9% decline in the 90 day share price return and a 57.3% fall in the 1 year total shareholder return, suggesting...
NasdaqGS:TSLA
NasdaqGS:TSLAAuto

Tesla’s EU FSD Breakthrough Puts Software Valuation Story in Focus

Tesla received regulatory approval for its Full Self-Driving supervised technology in the Netherlands after extensive testing. Dutch authorities have started the process for EU wide approval by formally notifying the European Commission. This is the first step that could allow Tesla's supervised autonomous driving system to be legally offered across the European Union. Tesla (NasdaqGS:TSLA) is drawing fresh attention as regulators in the Netherlands back its Full Self-Driving supervised...
NYSE:KMI
NYSE:KMIOil and Gas

Is Kinder Morgan (KMI) Pricing Reflecting Its Strong Multi‑Year Share Price Performance?

Before getting into the numbers, it helps to ask a simple question: at around US$31.65 per share, are you paying a fair price for Kinder Morgan or leaving value on the table? Recent returns have been mixed, with the share price down around 5.0% over the last week and 5.2% over the last month, while still showing a 14.2% gain year to date and 21.3% over the past year. Short-term moves like these often sit against a longer backdrop. In Kinder Morgan's case, the 3 year return is 109.7% and the 5...
NasdaqGS:TTWO
NasdaqGS:TTWOEntertainment

GTA VI Online Refresh Puts Take-Two’s Recurring Revenue Model In Focus

Take-Two Interactive Software (NasdaqGS:TTWO) is preparing a new iteration of GTA Online alongside the future launch of Grand Theft Auto VI. The refreshed GTA Online is expected to continue using in-game purchases that have supported recurring, high-margin revenue for the company over the past decade. Investors are watching how this updated online platform could influence the mix and stability of Take-Two's digital revenue profile. For anyone following NasdaqGS:TTWO, the focus now is less...
NasdaqGS:MTCH
NasdaqGS:MTCHInteractive Media and Services

A Look At Match Group (MTCH) Valuation After Recent Share Price Gains

Match Group stock snapshot after recent gains Match Group (MTCH) has drawn fresh attention after a recent stretch of gains, with the stock up about 9.1% over the past month and 5% over the past 3 months. See our latest analysis for Match Group. The recent 9.1% 30 day share price return and 5.8% year to date share price return sit against a mixed longer record, with an 18.3% 1 year total shareholder return but weaker 3 and 5 year total shareholder returns. This suggests momentum has picked up...
NasdaqGS:IDCC
NasdaqGS:IDCCSoftware

Is It Too Late To Consider InterDigital (IDCC) After A 75% One Year Surge?

If you are wondering whether InterDigital's share price still reflects its underlying value after a strong run, this breakdown is aimed at helping you frame that question clearly. The stock recently closed at US$352.32, with returns of 11.7% over 7 days, 8.0% year to date and 75.2% over 1 year, while the 3 year and 5 year returns are both very large. Recent headlines around InterDigital have focused on its role in software and licensing, along with ongoing interest in how its technology...
NYSE:ACI
NYSE:ACIConsumer Retailing

Albertsons Companies (ACI) Q3 Earnings Highlight Thin 1.1% Net Margin Pressure

Albertsons Companies (ACI) has put another quarter on the board, with Q3 FY 2026 revenue of US$19.1b, basic EPS of US$0.55 and net income of US$293.3m, plus same store sales growth of 2.4%. Over the past few quarters, the company has reported revenue of US$18.8b in Q2 FY 2026 and US$18.8b in Q3 FY 2025, rising to US$19.1b in the latest quarter. Basic EPS over the same periods was US$0.30 and US$0.69 respectively, before reaching US$0.55 in Q3 FY 2026. These figures set the scene for investors...
NYSE:ORI
NYSE:ORIInsurance

Is It Too Late To Consider Old Republic International (ORI) After Strong Multi‑Year Share Gains?

Investors may be wondering whether Old Republic International at around US$41.37 still offers value, or if most of the opportunity has already been priced in. The stock has returned 2.2% over the last 7 days and 3.2% over the past month. The year-to-date return is a 4.4% decline, while the 1-year return is 19.4%, with 3-year and 5-year returns of 101.0% and 157.6% respectively. This provides a mixed picture across different time frames. Recent coverage has focused on Old Republic...